Sign In
Buy WXXWY
$9.88
+0.180 (+1.86%)
At Close: Jul 31, 2026
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
04:30am, Friday, 19'th Dec 2025
SHANGHAI , Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership
WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
03:46am, Tuesday, 02'nd Dec 2025
DOHA, Qatar , Dec. 2, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has signed a strate
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
08:30pm, Tuesday, 21'st Oct 2025
The only company from pharmaceutical industry selected for inclusion in the Index Also included in HSI ESG Index and Hang Seng ESG 50 Index Green CRDMO solution provider with outstanding sustainabilit
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
05:30am, Monday, 20'th Oct 2025
SHANGHAI , Oct. 20, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been honored wit
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
08:30pm, Thursday, 09'th Oct 2025
SHANGHAI , Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ES
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has ach
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
12:00am, Tuesday, 23'rd Sep 2025
SHANGHAI , Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a c
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tibbi Cihaz Kurumu (TITCK)
12:00am, Wednesday, 17'th Sep 2025
WUXI, China , Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturi
WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards
09:30pm, Thursday, 11'th Sep 2025
SINGAPORE , Sept. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the "CDMO o
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
05:00am, Thursday, 28'th Aug 2025
Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Green CRDMO to drive innovation for a healthier future SHAN
WuXi Biologics Reports Solid 2025 Interim Results
08:35am, Tuesday, 19'th Aug 2025
Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net p
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
05:00am, Tuesday, 12'th Aug 2025
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substan
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Sta
WuXi Biologics Named to A List for CDP Supplier Engagement Assessment
08:30pm, Wednesday, 06'th Aug 2025
Earns CDP's highest rating for supply chain engagement on climate Adds to other CDP recognition—Water Security A List and leadership score on climate change Drives sustainability through value chain
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
06:00am, Wednesday, 16'th Jul 2025
Best ESG rating tier of negligible-risk with a top 1% global ranking score Industry and Regional ESG Top-Rated Company for five consecutive years Leader in Green CRDMO to drive innovation for a health
